Further engineering, such as arming with CARs, incorporating immune enhanced genes (e.g., IL-15), and depleting checkpoint molecules (e.g., PD-1 and CTLA-4), could improve the antitumor immunity of these therapeutic cells and provide an approach to simultaneously target both tumor and immunosuppressive cells. Here, CTLA4 is linked to neoplasm.